Investigating the Ligandin Activity of Schistosoma mansoni Glutathione S-Transferases Toward Testosterone: Implications for Novel Anthelminthic Drug Target Discovery

Schistosomiasis is a parasitic disease that affects more than 250 million people worldwide, causing chronic illness and significant suffering, particularly in sub-Saharan Africa. The only widely available treatment for this infection is a drug called praziquantel, which has been the cornerstone of control efforts for decades. However, scientists are growing concerned that the parasite is becoming less sensitive to this single drug, and there are very few alternatives. This creates an urgent need to find new ways to stop the worm, which requires understanding the specific biological tools the parasite uses to survive inside the human body. One of these tools is a family of proteins called glutathione S-transferases. These proteins act as a defense system for the parasite, helping it neutralize harmful chemicals and manage stress. Interestingly, these proteins also have a secondary ability to grab onto and transport other molecules, including hormones like testosterone, which the parasite uses to regulate its own growth and reproduction.

Researchers from institutions in Kenya and South Africa set out to investigate how these protective proteins in the parasite interact with testosterone. They wanted to know if testosterone could act as a weapon to kill the worm or if it simply interfered with the parasite's internal machinery. To test this, they exposed adult worms to testosterone in a laboratory setting and compared the results to worms treated with the standard drug, praziquantel. The results were immediate and clear. When exposed to praziquantel, the worms stopped moving almost instantly and died. In contrast, the worms treated with testosterone remained alive and active for the entire hour-long observation period. This finding ruled out the idea that testosterone acts as a direct poison to the worm. Instead, the researchers found that while the worms survived, the testosterone did something else: it significantly slowed down the activity of the protective proteins inside the worm's body.

To understand exactly how this slowdown happened, the team turned to computer modeling and detailed laboratory experiments. They built digital 3D models of the parasite's proteins and simulated how testosterone fits into them. These simulations revealed that testosterone does not block the main active site where the protein usually works. Instead, it binds to a specific pocket located at the junction where two protein units join together. When testosterone latches onto this spot, it acts like a wedge, forcing the protein to change its shape. The researchers confirmed this shape-shifting in the lab by studying real, purified versions of the proteins. They observed that when testosterone attached to the protein, the internal structure of the protein underwent a dramatic transformation, shifting from a coiled, spring-like arrangement to a flat, sheet-like structure. This structural change effectively jammed the protein's gears, reducing its ability to function by nearly half.

The study also looked at whether other molecules similar to testosterone might work even better. Using high-throughput virtual screening, the researchers tested a library of one hundred different steroid-like compounds on their computer models. They identified several analogues that appeared to bind more tightly to the protein than testosterone itself. When they simulated the behavior of these new compounds over long periods, the results suggested they could lock the protein into a stable, inactive state more effectively than the natural hormone. The research indicates that while testosterone alone is not a cure, it points to a specific vulnerability in the parasite's defense system. The proteins that the parasite relies on to survive are sensitive to these hormonal signals, and the way they change shape when bound suggests a new path for drug discovery. By designing drugs that mimic these hormones but bind more strongly, scientists may be able to develop a new class of treatments that disable the parasite's defenses without relying on the existing drug that is losing its effectiveness.